We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. is one of the best biotech stocks on this list.
TheFly reported on June 9 that Truist Securities initiated coverage of ZYME with a Buy rating and a $28 price target, down from $40. The firm highlighted ZYME as a balanced investment opportunity, supported by its royalty-based business model and expanding oncology pipeline that could provide long-term growth potential. Truist also pointed to pipeline assets, including Pasritamig in metastatic castration-resistant prostate cancer, as potential contributors due to upcoming clinical milestones.
Separately, on June 14, Zymeworks Inc. presented updated clinical findings from the dose-escalation phase of its ongoing Phase 1 trial assessing ZW191, an antibody-drug conjugate targeting folate receptor alpha. The data were presented at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026. Results showed encouraging anti-tumor activity in platinum-resistant ovarian cancer patients across different FRalpha expression levels. ZW191 achieved a confirmed objective response rate of 78.6% in FRalpha-positive patients and 47.4% in FRalpha-negative patients across evaluated dose levels. Median duration of response had not yet been reached, while median progression-free survival was 7.6 months across ovarian and endometrial cancer groups. Dose optimization enrollment was completed, with tolerability results supporting further clinical development.
Zymeworks Inc. is a clinical-stage biotechnology company developing next-generation cancer therapies, including multispecific antibodies and antibody-drug conjugates (ADCs).
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
